Method for differentiation into retinal cells from stem cells

Patent metadata

Field	Value
Publication number	US-9359592-B2
Application number	US-201013055709-A
Country	US
Kind code	B2
Filing date	Oct 6, 2010
Priority date	Oct 6, 2009
Publication date	Jun 7, 2016
Grant date	Jun 7, 2016

Abstract

Disclosed is a method for inducing stem cells to differentiate into retinal cells at high yield within a short period of time, without gene implantation and co-culture with retinal tissues, by implementing a differentiation process similar to the in vivo embryonic development in chemically defined conditions. Also, retinal cells including the photoreceptor cells and their progenitor cells, and various types of other retinal cells, generated according to the method, are disclosed. A composition comprising the retinal cells and a method are provided for treating retinal degeneration-related diseases. The differentiated photoreceptor cells, when transplanted into degenerated or injured retinas, can be engrafted and fused within the retinas to prevent or cure retinal degeneration.

First claim

The invention claimed is:

1. A method for differentiating stem cells into retinal cells, comprising:
(i) inducing stem cells to differentiate into eye field precursors in a form of floating aggregates by culturing stem cells in a medium containing an IGF1R activator, a Wnt signaling pathway inhibitor and a BMP signaling pathway inhibitor;
(ii) inducing the eye field precursors of step (i) to differentiate into retinal progenitor cells by culturing the eye field precursors in a medium containing IGF1R activator, a BMP signaling pathway inhibitor, an FGF signaling pathway activator and a Wnt signaling pathway inhibitor;
(iii) inducing the retinal progenitor cells of step (ii) to differentiate into neural retinal progenitor cells by culturing the retinal progenitor cells in a medium containing IGF1R activator, a BMP signaling pathway inhibitor, an FGF signaling pathway activator and a Wnt signaling pathway activator;
(iv) inducing the neural retinal progenitor cells of step (iii) to differentiate into photoreceptor cell precursors by culturing the neural retinal progenitor cells in a medium containing an IGF1R activator, a Wnt signaling pathway activator and an Shh (sonic hedgehog) signaling pathway activator; and
(v) inducing the photoreceptor cell precursors of step (iv) to differentiate into retinal cells, including photoreceptor cells, by culturing the photoreceptor cell precursors in a medium containing an IGF1R activator, a Wnt signaling pathway activator, an Shh signaling pathway activator and RA (retinoic acid).

2. The method as set forth in claim 1 , wherein the neural retinal progenitor cells are cultured for 1 to 30 days to generate the photoreceptor cell precursors.

3. The method according to claim 1 or 2 , wherein the stem cells are selected from the group consisting of bone marrow stem cells (BMSs), cord blood stem cells, amniotic fluid stem cells, fat stem cells, retinal stem cells (RSCs), intraretinal Müller glial cells, embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs) and somatic cell nuclear fusion cells (SCNT).

4. The method according to claim 1 or 2 , wherein the IGF1R activator is IGF-1 or IGF-2.

5. The method according to claim 1 or 2 , wherein the medium contains the IGF1R activator at a concentration of 0.01 to 100 ng/mL.

6. The method according to claim 1 or 2 , wherein the Wnt signaling pathway activator is selected from the group consisting of Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, Wnt16b; β-catenin expression level-increasing substances; GSK3 (glycogen synthase kinase 3) inhibitors selected from the group consisting of lithium (Li); LiCl, bivalent zinc (bivalent Zn), BIO (6-bromoindirubin-3′-oxime), SB216763, SB415286, CHIR99021, QS11 hydrate, TWS119, kenpaullone, alsterpaullone, indirubin-3′-oxime, TDZD-8, Ro 31-8220 methanesulfonate salt and a combination thereof; Axin inhibitors; APC (adenomatous polyposis coli) inhibitors; norrin; R-spondin 2; and a combination thereof.

7. The method as set forth in claim 6 , wherein the medium contains the Wnt signaling pathway activator selected from the group consisting of Wnt1, Wnt2, Wnt2b, Wnt3, Wnt3a, Wnt4, Wnt5a, Wnt5b, Wnt6, Wnt7a, Wnt7b, Wnt8a, Wnt8b, Wnt9a, Wnt9b, Wnt10a, Wnt10b, Wnt11, Wnt16b; β-catenin expression level-increasing substances; GSK3 (glycogen synthase kinase 3) inhibitors selected from the group consisting of lithium (Li), bivalent zinc (bivalent Zn), SB216763, CHIR99021, QS11 hydrate, TWS119, kenpaullone, alsterpaullone, indirubin-3′-oxime, TDZD-8, Ro 31-8220 methanesulfonate salt and a combination thereof; Axin inhibitors; APC (adenomatous polyposis coli) inhibitors; norrin; R-spondin 2; and a combination thereof at a concentration of 0.01 to 500 ng/ml.

8. The method as set forth in claim 6 , wherein when LiCl, BIO or SB415286 is used as a Wnt signaling pathway activator, the medium contains LiCl at a concentration of 0.1 to 50 mM; BIO at a concentration of 0.1 to 50 μM; and SB415286 at a concentration of 0.1 to 500 μM.

9. The method as set forth in claim 1 , wherein the Shh signaling pathway activator is selected from the group consisting of Shh, Smo (smoothened) receptor activators, inhibitors of Ptc (Patched) interaction with Smo, substances increasing Ci/Gli family levels, inhibitors of the intracellular degradation of Ci/Gli factors, Hg—Ag, purmorphamine, and a combination thereof.

10. The method as set forth in claim 1 , wherein the medium contains the Shh signaling pathway activator at a concentration of 0.1 to 5000 ng/mL.

11. The method as set forth in claim 1 , further comprising determining whether the differentiated cells are target cells or not.

12. The method as set forth in claim 11 , wherein the determining step is carried out by analyzing a gene characteristic of retinal progenitor cells, neural retinal progenitor cells, photoreceptor cell precursors or photoreceptor cells for mRNA or protein expression levels.

13. The method as set forth in claim 12 , wherein the gene characteristic of neural retinal progenitor cells is a combination of at least two genes selected from the group consisting of Rax, Pax6, Chx10 and Crx.

14. The method as set forth in claim 12 , wherein the gene characteristic of photoreceptor cell precursors is Crx or Nrl.

15. The method as set forth in claim 12 , wherein the gene characteristic of photoreceptor cells is selected from the group consisting of recoverin, rhodopsin, peripherin2, rom1, Pde6b, arrestin sag, phosducin, synaptophysin, red/green-opsin, blue-opsin and a combination thereof.

16. The method according to claim 1 or 2 , wherein the retinal cells are selected from the group consisting of photoreceptor cells, retinal ganglion cells, horizontal cells, bipolar cells, amacrine cells, Müller glial cells, retinal pigmented epithelial progenitor cells, retinal pigmented epithelium and combinations thereof.

17. The method as set forth in claim 16 , wherein the photoreceptor cells constitute more than 50% of a population of the retinal cells.

Assignees

• Park Sung Sup
• Kim Ji Yeon
• Snu R&Db Foundation

Inventors

• Park Sung Sup
• Kim Ji Yeon

Classifications

• C12N2501/998

  Proteins not provided for elsewhere · CPC title

• C12N2501/105

  Insulin-like growth factors [IGF] · CPC title

• C12N5/0621 Primary

  Eye cells, e.g. cornea, iris pigmented cells (photoreceptors C12N5/062) · CPC title

• C12N2501/155

  Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor · CPC title

• C12N2506/02

  from embryonic cells · CPC title